The objective of the study was to evaluate the frequency and clinical characteristics of ocular complications and their risk factors, as well as autologous serum tears (AST) for the treatment of dry eye in these patients. Data from the files of 124 patients who had undergone allogeneic haematopoietic progenitor cell transplantation (HPCT) were evaluated. In addition, 33 HPCT patients were examined and their data were compared with controls. Analysis of tears and AST was performed. Dry eye manifestation occurred in 32% of patients and was positively correlated with age over 27 years (P ¼ 0.05), peripheral blood progenitor cell transplant (P ¼ 0.002), chronic graft-versus-host disease (P ¼ 0.0027), and chronic or acute myeloid leukaemia (P ¼ 0.001). Dry mouth and Schirmer test o5 mm were predictive factors for dry eye in HPCT patients (P ¼ 0.002 and odds ratio 3.9 and P ¼ 0.007, odds ratio ¼ 5.9, respectively). Microbiological analysis revealed that six of 11 AST samples were contaminated after 30 days of use. The present study supports the role of potential risk factors for ocular complications and key elements to detect alterations in the tear film from HPCT patients. In addition, AST contamination must be considered after longer periods of use.
Introduction
The ocular alterations in patients submitted to haematopoietic progenitor cell transplantation (HPCT) have been described since the 1970s but not much is known about the risk factors or the mechanisms responsible for these alterations.
1,2 Among the ocular alterations are cataract, retinopathy, and dry eye. [3] [4] [5] Dry eye, defined as a deficiency in tear secretion and/or higher evaporation, is the most frequent alteration in HPCT patients, with a varying intensity of signs and symptoms, which may damage the ocular surface, increase the risk of infections and sometimes lead to serious loss of vision. 3, 6, 7 In previous studies, we have observed that inflamed lacrimal glands related to models of inflammatory diseases express higher levels of cytokines such as interleukin-1b (IL-1b) and tumor necrosis factor-a (TNF-a). 8 In addition, in recent studies we observed that insulin is secreted in tears, with its amount being regulated by local and systemic variables under normal conditions, and is involved in metabolic processes on the ocular surface. 9, 10 In patients submitted to bone marrow transplantation (BMT) the causes of dry eye have been attributed to the inflammatory process induced by graft-versus-host disease (GVHD), whose mechanism is related to donor's Tlymphocytes reaction against recipient's tissue alloantigens. The antigens present in the lacrimal gland, conjunctiva, and other tissues activate T lymphocytes, which proliferate and differentiate so that, along with other cells and inflammatory mediators, they destroy the cells of the host's tissues, compromising their function. 6, 7 In a recent study, (CD34 þ ) fibroblasts were identified mainly in periductal regions, with the proliferation of fibrosis in lacrimal glands of GVHD patients being attributed to these cells. 11 It has been demonstrated that in HPCT patients the peripheral blood progenitor cells (PBPC) present similar rate of acute GVHD as observed patients submitted to BMT, with shorter hospitalization time, but a higher rate of chronic GVHD. 12, 13 In a previous comparison, no significant difference in ocular complications was observed between the two techniques, but the small number of cases may have compromised the comparison. 14 In another study, age over 27 years, transplant from a different sex donor and a smaller number of (CD14 þ ) monocytes among transplanted cells led to a higher rate of acute and chronic GVHD. 15 Dry eye can occur in different stages, and has been treated with the occasional use of a lubricant, artificial tears, immunological suppressors, and cell proliferation stimulants such as autologous serum that combines lubricant, nutritional and defensive support for the ocular surface. 16, 17 Despite the comfort and stability of the ocular surface reached with these strategies, there is no cure for dry eye.
The objectives of the present study were to evaluate the risk factors for ocular damage, clinical manifestations and topical treatment in severe cases of dry eye. More specifically, we intended to (1) establish the frequencies of ocular manifestations, (2) to identify their risk factors, and (3) to evaluate the safety and efficacy of treatment with autologous serum as a tear substitute.
Patients and methods

Study design
Epidemiological and clinical data from 124 patients submitted to allogeneic HPCT between 1993 and 2003 were used for the present study. Ocular data were obtained from 33 HPCT patients and 10 control individuals who accepted the invitation to participate in the ocular examination and tear film collection. Signed informed consent was obtained from all participants.
Microbiological and biochemical data were collected from autologous serum tears (AST) of 12 patients who had been using it for more than 6 months.
The study was approved by the University Ethics Committee and respected the Declaration of Helsinki.
Epidemiological evaluation
The patients' charts were evaluated to identify epidemiological and clinical data (age, gender, previous ocular disease, and underlying haematological disease, previous treatment, cell source for transplant, whether autologous or allogeneic, transplant technique, whether bone marrow (BM) or PBPC, donor's characteristics, including gendermatch, immunosuppressor prophylaxis for GVHD, antimicrobial prophylaxis, and occurrence of acute and/or chronic GVHD.
Inclusion criteria were HPCT more than 6 months before and being alive at the time of chart data collection. Patients with pre-HPCT ocular alterations were excluded from the study.
Clinical evaluation
All the 124 patients whose files were examined were invited for an ophthalmologic exam, and 33 accepted the invitation. The patients were informed about the research and signed an informed consent term. They received a questionnaire about ocular discomfort in which the presence of pain, itching, foreign body sensation, redness, and irritant external factors (dust, light, wind, and air conditioning) were recorded and scored from 0 to 4 in intensity. Considering both eyes, five items and grades from 0 to 4, each patient could obtain a score ranging from 0 to 40, with 40 being considered the highest symptomatic stage. We also evaluated the presence of meibomian gland dysfunction (MGD), cataract, tear film break up time (TBUT) and keratitis, and applied the Schirmer, Rose Bengal and fluorescein tests, evaluated with National Eye Institute grading scale. 18 Data were compared with those for 10 age-and sexmatched volunteers recruited from the clinical staff and submitted to the same examination.
AST was prepared under sterile conditions as described elsewhere and microbiologic control of the AST preparation was routinely performed without contamination along of the period. 16 Patients using AST were instructed to maintain the flasks in the freezer and the in-use flask in the refrigerator. They were oriented about the risk of contamination and asked to contact the ophthalmologist in case of ocular irritation and/or discharge. In all visits, after reduction of punctate keratitis they were asked to compare AST with previous medications and were advised to move back to regular lubricants. They were requested to return the flasks they were using for evaluation 30 days after preparation.
A dry eye diagnosis was confirmed when at least one of these signs was present: TBUT p5 seconds, Schirmer's test o5 mm in 5 min, Rose Bengal 45, fluorescein 42, and score over five on the questionnaire. MGD was recorded when it compromised over 60% of the glands.
Laboratory evaluation
Tear samples were collected from 26 patients and seven control individuals with minimum stimulation and submitted to the IL-1b assay using an ELISA kit (Pierce Endogen, Rockford, IL, USA) according to the manufacturer's instructions. On another visit, tears were collected from patients with established dry eye related to HPCT and submitted to RIA for insulin levels and to the biuret dye test for protein evaluation as previously described and the data were compared to controls. 13 Seven patients and three controls were not included in the biochemical evaluation of tears because they did not satisfy the criteria of presence and absence of dry eye, respectively, or were unable to provide a sufficient volume for the assay.
Samples of autologous serum used by the patients as a tear substitute were collected 30 days after serum preparation, directly from the sample product remaining inside the bottles and cultured for bacteria and fungi, and the organisms present on the plates were identified. Autologous serum samples were also collected at days 0 and 30 to compare protein and insulin levels in order to evaluate sample degradation by RIA and by the biuret dye assay. 
Statistical analysis
Results
Epidemiologic data
Of 124 patients, 80 (64.5%) were men and 44 (35.5%) were women. Of them, 93 (75%) were white patients, 17 (13.7%) were black patients and 14 (11.3%) considered themselves to be of another race. Mean age was 31.5712.1 years, with a median of 31.5 and a range of 7.3-56.9 years. Four patients (3.2%) had received an ocular diagnosis before HPCT. All cases in this series were submitted to allogeneic HPCT.
Chronic myeloid leukaemia (CML) was the most frequent haematological disease with 67 (54%) cases, followed by severe aplastic anemia (SAA) with 25 (20.2%) cases, acute myeloid leukaemia (AML) with 19 (15.3%) cases, acute lymphoid leukaemia and myelodysplastic syndrome with five (4.0%) cases each, nonHodgkin's lymphoma with two (1.6%) cases, and multiple myeloma with one (0.8%) case.
For the transplant technique, 103 (83%) patients received BM and 21 (17%) PBPC as cell source. The donor-recipient gender distribution recipient was 38 (30.7%) from male to male recipient, 25 (20.2%) from male to female recipient, 37 (29.8%) from female to male recipient, and 24 (19.4%) from female to female recipient.
Acute GVHD grade II-IV was absent in 109 (87.9%) cases and was present in 15 (12.1%), manifested in the skin in seven (5.7%), in the gastrointestinal tract (GIT) in five (4.0%), in the liver in two (1.6%), and in the skin plus GIT in one (0.8%). Chronic GVHD occurred in 81 (65.3%) cases, 11 (8.9%) cases were hepatic, two (1.6%) were limited to the skin, 24 (19.4%) were localized in the skin and in another organ, 11 (8.9%) involved the eye, 26 (32%) involved the skin and other organs, and in seven (5.7%) one of the other organs involved were the eyes. The mean time to develop chronic GVHD symptoms was 9.1714.6 months, with a median of 92 days and a maximum of 111 months.
Dry eye was found in 40 (32.3%) patients. The mean time to develop dry eye was 39.778.5 months. There was a significant difference between patients submitted to BM (52.3711.9 months) and to PBPC (12.873.1 months) (P ¼ 0.006).
Other ocular alterations found were corneal opacity in seven (5.7%), with two (1.6%) being sequelae of herpes zoster keratitis and the others being related to ocular surface damage secondary to dry eye. Cataract occurred in four (3.3%) patients, retinal alteration in one (0.8%), and obstruction of the lacrimal drainage system in two (1.6%).
A lip biopsy showed an inflammatory infiltrate in the salivary glands of 60 (48.4%) patients. Autologous serum eye drops were used by nine (7.8%) patients.
The data collected from 33 patients examined indicated that the most frequent findings were a Rose Bengal score 45, found in 14 patients (42.4%), MGD in 14 (42.4%), TBUT p5 00 in 21 (64%), keratitis in 10 (30.3%), ocular discomfort in 19 (57.6%), and Schirmer test o5 mm in 10 (30.3%). Four patients (12.1%) with a previous diagnosis of dry eye were not confirmed in this evaluation and two (6.1%) considered normal satisfied at least one criterion of dry eye.
Correlations
According to the categorical analysis, there was a positive correlation between dry eye and age over 27 years (w (Table 1) .
There was no significant association between dry eye and recipient's gender (w 2 , P ¼ 0.5), donor and recipient gender match (w 2 , P ¼ 0.8), HLA compatibility (w 2 , P ¼ 0.12), GVHD prophylaxis, antibacterial, virus and fungus prophylaxis (Fisher's exact test, P40.6), or acute GVHD (Fisher's exact test, P ¼ 0.188).
Laboratory evaluation
To determine whether inflammatory cytokines were involved in the physiopathology of dry eye by at least one of the established criteria, the level of IL-1b in tears was compared to that obtained from controls. The results were 24.15714.32 pg/ml for HPCT-related dry eye (n ¼ 26) and 24.1978.29 pg/ml for normal controls (n ¼ 7) (P ¼ 0.99).
Insulin was quantified in order to evaluate the quality of tear secretion due the importance of insulin for tissue metabolism and its presence in various secretions. The data showed that insulin in the tear film was expressed at levels Table 1 Risk and predictive factors for dry eye in patients submitted to haematopoietic progenitor cell transplantation Dry eye and haematopoietic progenitor cell transplantation SC Leite et al of 0.8070.13 ng/ml in HPCT patients with GVHD and dry eye (n ¼ 5) and at levels of 1.1870.60 ng/ml in control subjects (n ¼ 9) (P ¼ 0.29). The protein levels in tears were 17.279.1 mg/ml in HPCT patients with GVHD and dry eye (n ¼ 5) and 4.6070.80 mg/ml in controls (n ¼ 9) (P ¼ 0.54).
Autologous serum evaluation
Analyses were conducted to investigate the potential contamination and viability of AST in HPCT patients with dry eye. The presence of insulin and protein was compared at days 0 and 30 and microbiological cultures were performed. Insulin levels in the AST were 2.3070.60 (n ¼ 9) at day 0 and 1.6070.70 ng/ml (n ¼ 5) at day 30 (P ¼ 0.84). Protein levels were 51.1072.70 at day 0 (n ¼ 9) and 50.7074.60 ng/ ml at day 30 (n ¼ 5) (P ¼ 0.47).
Eleven AST samples were analysed after 30 days of use by the patients. The data related to microbiological contamination are presented in Table 2 .
Discussion
Our findings confirm that dry eye is the major complication in these patients and indicate age over 27 years, CML, PBPC as cell source, and chronic GVHD as important risk factors, and a Schirmer test lower than 5 mm and dry mouth as predictive factors. We also describe our experience with AST.
Previous studies have identified the lacrimal glands as a source of lymphocytic infiltration in GVHD patients and have compared the dry eye syndrome to cases with Sjo¨gren syndrome. 19 Further studies have confirmed the similarity in histological analysis and the strong correlation between dry eye and dry mouth in these patients. Other clinical aspects that might correlate with Sjo¨gren syndrome were not confirmed by our observations, that is, a higher prevalence in female subjects and/or female immune system or sex hormone background. 20 Other previously suspected potential risk factors such as conditioning therapy, radiotherapy, and other medications used for prophylaxis, which may have a negative effect on tear film secretion, were not confirmed in our study. Multicentric comparisons with different treatment protocols will be needed to clarify these effects. 21 Chronic severe conjunctivitis without signs and symptoms of dry eye, as previously reported, was not seen in any of the cases followed up for 8 years, probably due to the fact that follow-up was started later when acute GVHD was more critical and because of the improvement of immunosuppressive therapy. With the corticosteroids being replaced with cyclosporine A. 22 Other studies have reported that dry eye was present in the absence of acute or chronic GVHD and vice versa, but a similar mean time of onset and a higher association of dry eye with chronic GVHD and older patients was also described. 5, 7 As we only evaluated the charts of living patients, there was a potential bias regarding acute GVHD and its relationship with dry eye and conjunctivitis since this association, although not frequent nowadays, has a higher lethal potential. 21 Our group recently reported the long-term histological findings in dry mouth related to HPCT. 23 Here, we observed that dry mouth and a low Schirmer test, which are easily evaluated by a questionnaire and by minor noninvasive procedures, could help detect initial cases of dry eye in these patients.
On the other hand, our attempt to characterize biochemically dry eye by the presence in tears of proinflammatory cytokines such as IL-1b or a marker of secretion such as insulin was not successful, because of a wide variation in the content of tear secretion. Previous studies have observed that traditional methods of clinical and laboratory diagnosis of dry eye have low sensitivity. Moreover, signs poorly correlate with symptoms in these cases. 24 However, perspectives may improve with recently improved methods for osmolarity assays in the tear film. 25 Autologous serum is useful in severe dry eye related to various diseases, and contains amounts of insulin similar to those present in blood and in the tear film, in addition to growth factors and other elements for the ocular surface. 16, 17, 26, 27 The safety of AST was observed in our series (with some of our patients using it for more than 5 years) and in others. 28 A previous study with commercially available preserved ocular medications chronically in-use by patients with ocular surface diseases revealed that 29% of them were contaminated, with a predominance of Gramnegative microorganisms. 29 This information and our data suggests that the frequency of pathogenic microorganisms is higher in patients with dry eye. On this basis, and considering the characteristics of AST, a precise protocol should be followed for the preparation and careful application of these medications with the support of haemotherapeutic services since contamination is a common complication in cases of prolonged use or misuse or conservation. 29, 30 In conclusion, the present study describes some clinical aspects useful to predict dry eye complications in HPCT Table 2 Microbiological culture of autologous serum eye drops used by patients undergoing bone marrow transplantation who developed dry eye
Patients
Culture result patients and recommends the use of AST with careful attention paid to the preparation and application procedures.
